SP2509

CHF 144.00
In stock
SYN-1212-M0011 mgCHF 144.00
SYN-1212-M0055 mgCHF 299.00
SYN-1212-M01010 mgCHF 467.00
SYN-1212-M05050 mgCHF 1'496.00
SYN-1212-M100100 mgCHF 2'334.00
 
More Information
Product Details
Synonyms SP-2509
Product Type Chemical
Properties
Formula C19H20ClN3O5S
MW 437.9
CAS 1423715-09-6
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: LSD1 | Kinase Group: N/A | Substrate: N/A

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key NKUDGJUBIVEDTF-FYJGNVAPSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.
Product References
  1. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors: V. Sorna, et al.; J. Med. Chem. 56 9496 (2013)
  2. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells: W. Fiskus, et al.; Leukemia 28, 2155 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.